You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Details for Patent: 8,637,512

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,637,512 protect, and when does it expire?

Patent 8,637,512 protects LAMICTAL XR and is included in one NDA.

This patent has forty-four patent family members in thirty countries.

Summary for Patent: 8,637,512

Title:	Formulations and method of treatment
Abstract:	A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.
Inventor(s):	Buxton; Ian Richard (Mississauga, CA), Karolak; Wlodzimierz (Mississauga, CA), Maleki; Mehran (Mississauga, CA), Iyer; Vijay Mohan (Mississauga, CA)
Assignee:	Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:	10/726,752
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,637,512
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,637,512

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-001	May 29, 2009	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-002	May 29, 2009	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-003	May 29, 2009	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-006	Jun 21, 2011	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-005	Apr 14, 2010	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,637,512

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0217492.8	Jul 29, 2002
United Kingdom	0217493.6	Jul 29, 2002
United Kingdom	0313801.3	Jun 13, 2003

International Family Members for US Patent 8,637,512

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040709	⤷ Sign Up
Austria	424827	⤷ Sign Up
Australia	2003260336	⤷ Sign Up
Brazil	0313148	⤷ Sign Up
Brazil	PI0313148	⤷ Sign Up
Canada	2493301	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.